< Back to topics
> Cover Page, Authors, Institutions
> Purpose/Objective
> Materials/Methods
> Results/Discussion
> Conclusions
> View tables/images/videos
> View abstract & virtual poster in original format
|
|
Materials/Methods:
523 patients underwent trimodality therapy for the treatment of non-metastastic prostate cancer. The presenting risk groups were low (large volume Gleason 6) in 2%, intermediate in 23% and high in 75%. Clinical stage was < t1c in 26%, t2a in 16%, t2b in 29%, t2c in 22% and > t3a in 7%. Gleason score was < 6 in 21%, 7 in 50% and > 8 in 29%. Presenting PSA was < 10 in 52%, >10-20 in 30% and > 20 in 18%. Trimodality therapy consisted of 3-9 months of hormonal therapy, a Pd-103 implant (prescription dose - 100Gy) and 45 Gy of EBRT. The BED for these treatments ranged from 148 to 280 (median - 205) using an alpha/beta ratio of 2. Patients were followed from 2 to 11 years (median 4.4). PSA failure was calculated using the ASTRO, PHNX and AUA definitions.
|
|
